淋巴瘤患者血栓风险预测:多机构回顾性模型开发与验证研究
本研究基于退伍军人事务部全国医疗系统(VA)的10313例成人淋巴瘤患者,回顾性开发Fine和Gray亚分布风险模型分别预测静脉血栓栓塞(VTE)和肺栓塞(PE)/下肢深静脉血栓(LE-DVT),并在Harris Health System(HHS)854例和MD Anderson癌症中心(MDACC)1858例患者中外部验证。最终风险评估模型(RAM)纳入淋巴瘤组织学、体重指数、治疗类型、近期住院、VTE病史、瘫痪/制动史及治疗启动时间,推导队列c统计量为0.68,两个外部验证队列分别为0.69和0.72。
要点
- 6个月VTE发生率:VA队列5.8%、HHS队列8.2%、MDACC队列8.8%。
- 6个月PE/LE-DVT发生率:VA队列3.9%、HHS队列4.5%、MDACC队列3.7%。
- RAM的c统计量:推导队列0.68,外部验证队列0.69和0.72。
核心结论
- 研究结果提示,一种易于实施的、基于临床的模型可用于预测淋巴瘤患者的个体化VTE风险。
研究设计与样本
- 回顾性队列研究,在VA全国医疗系统的成人淋巴瘤患者中开发Fine和Gray亚分布风险模型分别预测VTE和PE/LE-DVT,并在HHS和MDACC进行外部验证。
- 推导队列10313例(VA),外部验证队列854例(HHS)和1858例(MDACC),基线特征多样。
- 采用时间依赖c统计量和校准曲线评估区分度与拟合度。
主要发现
- 6个月VTE发生率:VA队列5.8%、HHS队列8.2%、MDACC队列8.8%。
- 6个月PE/LE-DVT发生率:VA队列3.9%、HHS队列4.5%、MDACC队列3.7%。
- 最终RAM纳入变量:淋巴瘤组织学、体重指数、治疗类型、近期住院、VTE病史、瘫痪/制动史、治疗启动时间。
- RAM的c统计量:推导队列0.68,HHS验证队列0.69,MDACC验证队列0.72。
- 两个模型在各队列中均实现了风险分层的清晰区分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venous thromboembolism (VTE) poses a significant risk to cancer patients receiving systemic therapy. The generalizability of pan-cancer models to lymphomas is limited. Currently, there are no reliable risk prediction models for thrombosis in patients with lymphoma. Our objective was to create a risk assessment model (RAM) specifically for lymphomas. We performed a retrospective cohort study to develop Fine and Gray sub-distribution hazard model for VTE and pulmonary embolism (PE)/ lower extremity deep vein thrombosis (LE-DVT) respectively in adult lymphoma patients from the Veterans Affairs national healthcare system (VA). External validations were performed at the Harris Health System (HHS) and the MD Anderson Cancer Center (MDACC). Time-dependent c-statistic and calibration curves were used to assess discrimination and fit. There were 10,313 (VA), 854 (HHS), and 1858 (MDACC) patients in the derivation and validation cohorts with diverse baseline. At 6 months, the VTE incidence was 5.8% (VA), 8.2% (HHS), and 8.8% (MDACC), respectively. The corresponding estimates for PE/LE-DVT were 3.9% (VA), 4.5% (HHS), and 3.7% (MDACC), respectively. The variables in the final RAM included lymphoma histology, body mass index, therapy type, recent hospitalization, history of VTE, history of paralysis/immobilization, and time to treatment initiation. The RAM had c-statistics of 0.68 in the derivation and 0.69 and 0.72 in the two external validation cohorts. The two models achieved a clear differentiation in risk stratification in each cohort. Our findings suggest that easy-to-implement, clinical-based model could be used to predict personalized VTE risk for lymphoma patients.
引用
- Ma S, La J, Swinnerton KN, et al. Thrombosis risk prediction in lymphoma patients: A multi-institutional, retrospective model development and validation study. Am J Hematol. 2024. PMID: 38654461. doi:10.1002/ajh.27335
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。